Prophylaxis News and Research

RSS

Dabigatran etexilate cost-effective compared to current care for stroke prevention in AF patients

A new health economic analysis, published today online in Thrombosis and Haemostasis, suggested that Boehringer Ingelheim's novel oral direct thrombin inhibitor, dabigatran etexilate, is cost-effective compared to current treatment options, particularly in "real-world" clinical practice.

23 Mar 2011

CHMP recommends approval of Centralized Marketing Authorization for Cinryze

ViroPharma Incorporated today announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted a positive opinion at its plenary meeting in March 2011 recommending approval of a Centralized Marketing Authorization for Cinryze (C1 inhibitor [human]) in adults and adolescents with hereditary angioedema for routine prevention, pre-procedure prevention and acute treatment of angioedema attacks.

19 Mar 2011

African delegates call on countries to do more to prevent mother-to-child transmission of HIV

Delegates from 15 African countries this week concluded a three-day workshop held in Nairobi, Kenya, examining how countries can improve their efforts to prevent mother-to-child transmission of HIV, VOA News reports.

19 Mar 2011

Experts issue joint statement to help Americans understand radiation-related health risks

The growing concern surrounding the release of radiation from an earthquake and tsunami-stricken nuclear complex in Japan has raised fears of radiation exposure to populations in North America from the potential plume of radioactivity crossing the Pacific Ocean.

19 Mar 2011

Anacor Pharma, MMV enter agreement to develop AN3661 for malaria treatment

Anacor Pharmaceuticals announced today that it has entered into a development agreement with Medicines for Malaria Venture to develop Anacor's compound AN3661 for the treatment of malaria.

18 Mar 2011

Nationwide observance raises awareness about HIV/AIDS spread in women

National Women and Girls AIDS Awareness Day, a nationwide observance that raises awareness and promotes action in the fight against HIV/AIDS, took place on March 10.

17 Mar 2011

Additional research needed for oral PrEP to treat HIV

The first human studies of an oral drug regimen to prevent HIV infection in high-risk individuals yielded a promising near 50% reduction in HIV incidence, but a number of issues require additional research before oral pre-exposure prophylaxis can be implemented on a large scale, according to an article in AIDS Patient Care and STDs, a peer-reviewed journal published by Mary Ann Liebert, Inc.

15 Mar 2011

New PTLD Guideline highlighted at NCCN Annual Conference

A new Guideline detailing diagnosis, workup, and treatment options for Post-Transplant Lymphoproliferative Disorder, as well as stronger recommendations for therapies in follicular lymphoma, topped the list of highlights in a presentation of the updated NCCN Guidelines for Non-Hodgkin's Lymphomas.

14 Mar 2011

AHF unveils new national advertising campaign about AIDS drugs

AIDS Healthcare Foundation today unveiled a new national advertising campaign headlined, "There Is No Magic Pill," an advocacy and awareness campaign to educate and prompt discussion among gay men and others regarding Gilead Sciences and its likely plans to seek Food and Drug Administration approval for use of its blockbuster AIDS drug Truvada as a form a 'pre-exposure prophylaxis' to prevent HIV transmission.

10 Mar 2011

Conflicts in medical management of hemophilia

Hemophilia is a medical disorder that is part of our genetic load as humans. It will never disappear. Therefore, the only way to live with it is to receive adequate medical management. Its effects on those males who have inherited the disorder that affects their blood clotting without treatment includes recurrent hemorrhages (bleeds) into joints as well as internal bleeding. The bleeds are painful, resulting in disuse, disability and crippling. The first signs usually appear in early childhood. A child who suffers a mouth bleed can slowly lose enough blood to result in death.

8 Mar 2011

Anacor and iOWH establish research agreement to identify new drugs for shigellosis

Anacor Pharmaceuticals (NASDAQ:ANAC) and the Institute for OneWorld Health (iOWH) today announced the establishment of a joint research agreement to discover antibacterial compounds for treating shigellosis.

8 Mar 2011

HIV prevention, treatment highlighted at Conference on Retroviruses and Opportunistic Infections

Today was the last day of the 18th Conference on Retroviruses and Opportunistic Infections, a key HIV/AIDS research meeting being held at the Hynes Convention Center in Boston from February 27 through March 2. Highlighted below are selected presentations from March 2nd on research supported by the National Institute of Allergy and Infectious Diseases and the Eunice Kennedy Shriver National Institute of Child Health and Human Development, both components of the National Institutes of Health.

5 Mar 2011

Pediatrician unveils latest findings of IMPAACT HIV/AIDS study during 2011 CROI

A clinical study of anti-HIV/AIDS medicines in the developing world is on the verge of turning "the whole treatment world on its head," according to Dartmouth pediatrician Paul Palumbo.

4 Mar 2011

Seven-year study finds Group B strep as main cause of newborn bacterial meningitis

The Group B Streptococcus is still the most common cause of bacterial meningitis in newborns, concludes a seven-year French study in the March issue of The Pediatric Infectious Disease Journal.

3 Mar 2011

Baxter announces European rMRP approval of PREFLUCEL seasonal influenza vaccine

Baxter International Inc. announced today the approval of a European repeat mutual recognition procedure (rMRP) by the Austrian Agency for Health and Food Safety for Baxter's PREFLUCEL seasonal influenza vaccine. The 13 participating European Union countries, including Germany, Spain, United Kingdom and Nordic countries, will formally implement the license on a national level to make PREFLUCEL available for the 2011-12 influenza season.

From Baxter International Inc. 2 Mar 2011

Scientists at retrovirus conference present findings on microbicide gel, Truvada, male circumcision, ART care by nurses

At the annual Conference on Retroviruses and Opportunistic Infections (CROI) in Boston on Monday, researchers "suggested the potential" of a gel containing the antiretroviral drug tenofovir to reduce the risk of anal HIV transmission, TIME's "Healthland" blog reports.

2 Mar 2011

Tenofovir gel more effective than oral tablet for HIV treatment: Study

In the first study to make head-to-head comparisons between tenofovir gel and oral tenofovir - two promising approaches for preventing HIV in women - researchers found that daily use of the vaginal gel achieved a more than 100-times higher concentration of active drug in vaginal tissue than did the oral tablet, while, compared to the gel, the tablet used daily was associated with a 20-times higher active drug concentration in blood.

1 Mar 2011

Tenofovir gel may help reduce risk of HIV from anal sex

A gel developed to protect against HIV during vaginal sex produced a strong antiviral effect when used in the rectum, according to an early-phase study presented today at the 18th Conference on Retroviruses and Opportunistic Infections (CROI). The results, based on rectal tissue biopsies sampled from HIV-negative men and women who used the product daily for one week, provide the first-ever evidence that tenofovir gel could help reduce the risk of HIV from anal sex, even though the vaginal gel formulation may not be optimal for rectal use.

28 Feb 2011

The Lancet publishes Baxter's PREFLUCEL phase III trial results against seasonal influenza

Baxter International Inc. announced today results of a study published in this week's issue of The Lancet that demonstrate effectiveness and tolerability of Baxter's PREFLUCEL in protecting against seasonal influenza.

From Baxter International Inc. 15 Feb 2011

Janssen, Medivir collaborate to discover and develop drugs against dengue virus

Medivir AB, the emerging research-based specialty pharmaceutical company focused on infectious diseases, announces today that it has signed a collaboration agreement with Janssen Pharmaceutica N.V. for the discovery and development of drugs for the prophylaxis and treatment of dengue virus infection.

14 Feb 2011

Prophylaxis News and Research

Dabigatran etexilate cost-effective compared to current care for stroke prevention in AF patients

CHMP recommends approval of Centralized Marketing Authorization for Cinryze

African delegates call on countries to do more to prevent mother-to-child transmission of HIV

Experts issue joint statement to help Americans understand radiation-related health risks

Anacor Pharma, MMV enter agreement to develop AN3661 for malaria treatment

Nationwide observance raises awareness about HIV/AIDS spread in women

Additional research needed for oral PrEP to treat HIV

New PTLD Guideline highlighted at NCCN Annual Conference

AHF unveils new national advertising campaign about AIDS drugs

Conflicts in medical management of hemophilia

Anacor and iOWH establish research agreement to identify new drugs for shigellosis

HIV prevention, treatment highlighted at Conference on Retroviruses and Opportunistic Infections

Pediatrician unveils latest findings of IMPAACT HIV/AIDS study during 2011 CROI

Seven-year study finds Group B strep as main cause of newborn bacterial meningitis

Baxter announces European rMRP approval of PREFLUCEL seasonal influenza vaccine

Scientists at retrovirus conference present findings on microbicide gel, Truvada, male circumcision, ART care by nurses

Tenofovir gel more effective than oral tablet for HIV treatment: Study

Tenofovir gel may help reduce risk of HIV from anal sex

The Lancet publishes Baxter's PREFLUCEL phase III trial results against seasonal influenza

Janssen, Medivir collaborate to discover and develop drugs against dengue virus

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News